|
Showing 1 - 4 of
4 matches in All Departments
Since the last edition of this book, major advances have been made
in our understanding of key pathways that control tumor
progression. This has led to the development of new anticancer
agents that have the ability to block the activity of proteins
involved in neoplastic cell development and proliferation. Targeted
Therapies in Oncology, Second Edition provides a concise timely
panorama of existing targeted therapies and progress into future
anticancer treatments. These therapies notably include: Targeted
agents of immune checkpoints Signal-transduction inhibitors
Antiangiogenic agents Vascular-disrupting agents Apoptosis
modulators Stem cell inhibitors Tumor profiling for drug
development The book emphasizes the biology behind this new class
of drugs as well as the clinical achievements obtained. The
contributors to this volume stand at the cutting edge of cancer
research and treatment around the world.
Since the last edition of this book, major advances have been made
in our understanding of key pathways that control tumor
progression. This has led to the development of new anticancer
agents that have the ability to block the activity of proteins
involved in neoplastic cell development and proliferation. Targeted
Therapies in Oncology, Second Edition provides a concise timely
panorama of existing targeted therapies and progress into future
anticancer treatments. These therapies notably include: Targeted
agents of immune checkpoints Signal-transduction inhibitors
Antiangiogenic agents Vascular-disrupting agents Apoptosis
modulators Stem cell inhibitors Tumor profiling for drug
development The book emphasizes the biology behind this new class
of drugs as well as the clinical achievements obtained. The
contributors to this volume stand at the cutting edge of cancer
research and treatment around the world.
The development of drug-resistant cancers is considered to be the
most significant obstacle to the cure of cancer today. Nearly half
of all patients with cancer suffer from tumours that are
intrinsically resistant to chemotherapy, and most of the remaining
half develop drug resistance during the course of their treatment.
This book reviews the mechanisms and clinical implications of drug
resistance in cancer with unrivalled authority. Chapters cover
topics of current clinical concern, including multiple drug
resistance and its reversal, topoisomerase drugs, apoptosis, dose
intensity and escalation, gene therapy and haematopoietic support.
The authors are among the leading clinicians and investigators in
the field. These authoritative volumes in this series are intended
for a wide audience of clinicians and researchers with an interest
in the applications of biomedical science to the understanding and
management of cancer.
The development of drug-resistant cancers is considered to be the
most significant obstacle to the cure of cancer today. Nearly half
of all patients with cancer suffer from tumours that are
intrinsically resistant to chemotherapy, and most of the remaining
half develop drug resistance during the course of their treatment.
This book reviews the mechanisms and clinical implications of drug
resistance in cancer with unrivalled authority. Chapters cover
topics of current clinical concern, including multiple drug
resistance and its reversal, topoisomerase drugs, apoptosis, dose
intensity and escalation, gene therapy and haematopoietic support.
The authors are among the leading clinicians and investigators in
the field. These authoritative volumes in this series are intended
for a wide audience of clinicians and researchers with an interest
in the applications of biomedical science to the understanding and
management of cancer.
|
You may like...
It: Chapter 1
Bill Skarsgård
Blu-ray disc
R111
Discovery Miles 1 110
|